구강캔디다증 환자의 항진균 치료
(주)코리아스칼라
- 최초 등록일
- 2023.04.05
- 최종 저작일
- 2017.04
- 11페이지/
어도비 PDF
- 가격 4,200원
* 본 문서는 배포용으로 복사 및 편집이 불가합니다.
서지정보
ㆍ발행기관 : 대한구강악안면병리학회
ㆍ수록지정보 : 대한구강악안면병리학회지 / 41권 / 2호
ㆍ저자명 : 김해영, 강재국, 임영관, 김병국, 김혜은, 조혜중, SUNQIAOCHU, 안규현, SHISHUHAN, 김옥준
영어 초록
The aim of this study was to examine the effects and the sensitivity of antifungal therapy for patients with oral candidiasis and to investigate the relationship among the signs symptoms of patients and the ratio change of Candida species to antifungal therapy. Candida fungus culture test with ChromeIDTM Candida agar (CAN2) was carried out more than twice for 10 patients who visited Oral Medicine department of Chonnam National University Dental Hospital during the period from Dec. 2015 to Aug. 2016. After culturing the smear sample before and after antifungal therapy in ChromeIDTM Candida agar (CAN2), the number of colonies was counted to compare. Patients were divided into 5 group according to the therapeutic effects of the antifungal agents used: 1) high susceptibility to nystatin, 2) low susceptibility to nystatin, 3) high susceptibility to fluzonazole, 4) low susceptibility to fluzonazole, and 5) increased ratio of new Candida species. Although nystatin is used as first-line therapy in oral candidiasis, it is desirable to use fluconazole if patients had a history of the low sensitivity to nystatin or chemotherapy. Even if the patients symptoms and signs are improved, there is a possibility of oral candidiasis recurring, so that clinicians should be careful during the treatment with antifungal agents.
참고 자료
없음
